Kriptic Pharmaceuticals Limited
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
3
Ending by 2030
Jun 2028
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
No maintenance fee falls due on this company's record before Nov 21, 2027.
Recent changes
- 1 of the patents on this record was granted since Aug 23, 2026
- Sep 8 US 12,728,158 Combination of Markers for Predicting the Response to Vx-001
- 1 term has ended since Aug 23, 2026
- Sep 30 US 7,973,128 Immunogenic polypeptide composed of tumor antigen-derived optimized cryptic peptides, and uses thereof · term ended
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 6 of 6
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,663,645 | Use of native peptides and their optimized derivatives for vaccination In force · USPTO record | In force | USPTO record | |
| US 8,900,600 | Identification, optimization and use of cryptic HLA-A24 epitopes for immunotherapy In force · USPTO record | In force | USPTO record | |
| US 8,465,747 | Identification, optimization and use of cryptic HLA-B7 epitopes for immunotherapy In force · USPTO record | In force | USPTO record | |
| US 10,024,868 | Identification, optimization and use of shared HLA-B*0702 epitopes for immunotherapy In force · USPTO record | In force | USPTO record | |
| US 12,048,737 | Use of a Vaccine Targeting a Cryptic Tert Epitope, for Treating Cancer in a HLA-A*0201-Positive Patient Having a Non-Immunogenic Tumor Expressing Tert In force · Medium confidence | In force | Medium confidence | |
| US 12,728,158 | Combination of Markers for Predicting the Response to Vx-001 In force · Medium confidence | In force | Medium confidence |
Also on record, not counted in the 6: 1 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
1 pending
Showing 1 to 1 of 1, newest filing first. An application has no patent term. A term is computed when and if it grants, and appears on that patent's own page.
| Application | Title | Filed | Status |
|---|---|---|---|
| 18/744,060 | Use of a Vaccine Targeting a Cryptic Tert Epitope, for Treating Cancer in a HLA-A*0201-Positive Patient Having a Non-Immunogenic Tumor Expressing Tert | Jun 14, 2024 | Pending |